EGFR-Targeted TKIs Continue to Have Outsized Impact in NSCLC

Thomas J. Lynch Jr, MD, details how treatments are evolving for patients with EGFR-mutated advanced non–small cell lung cancer.

Related Keywords

Washington , United States , Seattle , Hollywood , California , Lynch Jr , Thomasj Lynch Jr , Fred Hutch Cancer Center , Winter Lung Cancer , Raisbeck Endowed Chair , Lung Cancer , Amivantamab Treating Exon , Examining Osimertinib , Cancer Care Lecture , Winter Lung Cancer Conference , D , Patients With Egfr Mutated Advanced Non Small Cell Lung Cancer ,